These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

638 related articles for article (PubMed ID: 15897883)

  • 1. Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice.
    Landis MD; Seachrist DD; Montañez-Wiscovich ME; Danielpour D; Keri RA
    Oncogene; 2005 Aug; 24(33):5173-90. PubMed ID: 15897883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors.
    Landis MD; Seachrist DD; Abdul-Karim FW; Keri RA
    Oncogene; 2006 Jun; 25(23):3325-34. PubMed ID: 16434967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
    Kim A; Liu B; Ordonez-Ercan D; Alvarez KM; Jones LD; McKimmey C; Edgerton SM; Yang X; Thor AD
    Breast Cancer Res; 2005; 7(5):R708-18. PubMed ID: 16168116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study.
    Xie W; Mertens JC; Reiss DJ; Rimm DL; Camp RL; Haffty BG; Reiss M
    Cancer Res; 2002 Jan; 62(2):497-505. PubMed ID: 11809701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of three new mouse mammary tumor cell lines as models for transforming growth factor (TGF)-beta and Neu pathway signaling studies: identification of a novel model for TGF-beta-induced epithelial-to-mesenchymal transition.
    Lenferink AE; Magoon J; Cantin C; O'Connor-McCourt MD
    Breast Cancer Res; 2004; 6(5):R514-30. PubMed ID: 15318933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptional cooperation between the transforming growth factor-beta and Wnt pathways in mammary and intestinal tumorigenesis.
    Labbé E; Lock L; Letamendia A; Gorska AE; Gryfe R; Gallinger S; Moses HL; Attisano L
    Cancer Res; 2007 Jan; 67(1):75-84. PubMed ID: 17210685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
    Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
    Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling.
    Lo PK; Kanojia D; Liu X; Singh UP; Berger FG; Wang Q; Chen H
    Oncogene; 2012 May; 31(21):2614-26. PubMed ID: 21996747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wnt pathway component LEF1 mediates tumor cell invasion and is expressed in human and murine breast cancers lacking ErbB2 (her-2/neu) overexpression.
    Nguyen A; Rosner A; Milovanovic T; Hope C; Planutis K; Saha B; Chaiwun B; Lin F; Imam SA; Marsh JL; Holcombe RF
    Int J Oncol; 2005 Oct; 27(4):949-56. PubMed ID: 16142310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activin type II receptor restoration in ACVR2-deficient colon cancer cells induces transforming growth factor-beta response pathway genes.
    Deacu E; Mori Y; Sato F; Yin J; Olaru A; Sterian A; Xu Y; Wang S; Schulmann K; Berki A; Kan T; Abraham JM; Meltzer SJ
    Cancer Res; 2004 Nov; 64(21):7690-6. PubMed ID: 15520171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of periostin/OSF-2 in ErbB2/Neu-driven tumors results in androgen receptor-positive molecular apocrine-like tumors with reduced Notch1 activity.
    Sriram R; Lo V; Pryce B; Antonova L; Mears AJ; Daneshmand M; McKay B; Conway SJ; Muller WJ; Sabourin LA
    Breast Cancer Res; 2015 Jan; 17(1):7. PubMed ID: 25592291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heat shock factor Hsf1 cooperates with ErbB2 (Her2/Neu) protein to promote mammary tumorigenesis and metastasis.
    Xi C; Hu Y; Buckhaults P; Moskophidis D; Mivechi NF
    J Biol Chem; 2012 Oct; 287(42):35646-35657. PubMed ID: 22847003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells.
    Wilson CA; Cajulis EE; Green JL; Olsen TM; Chung YA; Damore MA; Dering J; Calzone FJ; Slamon DJ
    Breast Cancer Res; 2005; 7(6):R1058-79. PubMed ID: 16457687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral administration of a gemini vitamin D analog, a synthetic triterpenoid and the combination prevents mammary tumorigenesis driven by ErbB2 overexpression.
    So JY; Wahler JE; Yoon T; Smolarek AK; Lin Y; Shih WJ; Maehr H; Uskokovic M; Liby KT; Sporn MB; Suh N
    Cancer Prev Res (Phila); 2013 Sep; 6(9):959-70. PubMed ID: 23856074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conditional overexpression of liver receptor homolog-1 in female mouse mammary epithelium results in altered mammary morphogenesis via the induction of TGF-β.
    Lazarus KA; Brown KA; Young MJ; Zhao Z; Coulson RS; Chand AL; Clyne CD
    Endocrinology; 2014 May; 155(5):1606-17. PubMed ID: 24564400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenoviral gene transfer allows Smad-responsive gene promoter analyses and delineation of type I receptor usage of transforming growth factor-beta family ligands in cultured human granulosa luteal cells.
    Kaivo-Oja N; Mottershead DG; Mazerbourg S; Myllymaa S; Duprat S; Gilchrist RB; Groome NP; Hsueh AJ; Ritvos O
    J Clin Endocrinol Metab; 2005 Jan; 90(1):271-8. PubMed ID: 15483083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transforming growth factor {beta} (TGF-{beta})-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-{beta} function.
    Wang SE; Wu FY; Shin I; Qu S; Arteaga CL
    Mol Cell Biol; 2005 Jun; 25(11):4703-15. PubMed ID: 15899872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Localization of activin and inhibin subunits, receptors and SMADs in the mouse mammary gland.
    Jeruss JS; Santiago JY; Woodruff TK
    Mol Cell Endocrinol; 2003 May; 203(1-2):185-96. PubMed ID: 12782414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting FACT complex suppresses mammary tumorigenesis in Her2/neu transgenic mice.
    Koman IE; Commane M; Paszkiewicz G; Hoonjan B; Pal S; Safina A; Toshkov I; Purmal AA; Wang D; Liu S; Morrison C; Gudkov AV; Gurova KV
    Cancer Prev Res (Phila); 2012 Aug; 5(8):1025-35. PubMed ID: 22689915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The nuclear receptor coactivator amplified in breast cancer-1 is required for Neu (ErbB2/HER2) activation, signaling, and mammary tumorigenesis in mice.
    Fereshteh MP; Tilli MT; Kim SE; Xu J; O'Malley BW; Wellstein A; Furth PA; Riegel AT
    Cancer Res; 2008 May; 68(10):3697-706. PubMed ID: 18483252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.